Oncology
19. Dec 2018
Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients
BACKGROUND:
Excessive extracellular matrix (ECM) remodeling and a reactive stroma can affect T-cell infiltration and T-cell activity in the tumor and hereby influence response to immune checkpoint inhibitors (ICI). In the pursuit of finding biomarkers that predict treatment response, we evaluated t…
Read the publication
Journal:
Authors:
- Jensen C,
- Madsen DH,
- Hansen M,
- Schmidt H,
- Svane IM,
- Karsdal MA,
- Willumsen N,
Oncology
19. Dec 2018
Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients (1)
Background
Excessive extracellular matrix (ECM) remodeling and a reactive stroma can affect T-cell infiltration and T-cell activity in the tumor and hereby influence response to immune checkpoint inhibitors (ICI). In the pursuit of finding biomarkers that predict treatment response, we evaluated th…
Read the publication
Journal:
Authors:
- Jensen C,
- Madsen D,
- Hansen M,
- Schmidt H,
- Svane IM,
Oncology, Colorectal, Gastrointestinal, Inflammatory Bowel Disease
20. Jul 2018
Serum type XVI collagen is associated with colorectal cancer and ulcerative colitis indicating a pathological role in gastrointestinal disorders
Altered extracellular matrix (ECM) remodeling is an important part of the pathology of gastrointestinal (GI) disorders. In the intestine, type XVI collagen (col-16) plays a role in pathogenesis by affecting ECM architecture and induce cell invasion. Measuring col-16 in serum may therefore have bioma…
Read the publication
Journal:
Authors:
- Jensen C,
- Nielsen SH,
- Mortensen JH,
- Kjeldsen J,
- Klinge LG,
- Harling H,
- Jørgensen LN,
- Karsdal MA,
- Willumsen N,
- Leeming DJ,
Oncology, Extracellular Matrix Research
11. Oct 2017
Quantification of altered tissue turnover in a liquid biopsy: a proposed precision medicine tool to assess chronic inflammation and desmoplasia associated with a pro-cancerous niche and response to immuno-therapeutic anti-tumor modalities
Immuno-therapy has begun to revolutionize cancer treatment. However, despite the significant progress achieved in regard to the duration of clinical benefits, a substantial number of patients do not respond to these therapies. To improve the outcome of patients receiving immuno-therapy, there is a n…
Read the publication
Journal:
Authors:
- Willumsen N,
- Thomsen LB,
- Bager CL,
- Jensen C,
- Karsdal MA,